RT Journal Article
SR Electronic
T1 Phylogenetic analysis of SARS-CoV-2 in the Boston area highlights the role of recurrent importation and superspreading events
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.08.23.20178236
DO 10.1101/2020.08.23.20178236
A1 Lemieux, Jacob E.
A1 Siddle, Katherine J.
A1 Shaw, Bennett M.
A1 Loreth, Christine
A1 Schaffner, Stephen F.
A1 Gladden-Young, Adrianne
A1 Adams, Gordon
A1 Fink, Timelia
A1 Tomkins-Tinch, Christopher H.
A1 Krasilnikova, Lydia A.
A1 DeRuff, Katherine C.
A1 Rudy, Melissa
A1 Bauer, Matthew R.
A1 Lagerborg, Kim A.
A1 Normandin, Erica
A1 Chapman, Sinead B.
A1 Reilly, Steven K.
A1 Anahtar, Melis N.
A1 Lin, Aaron E.
A1 Carter, Amber
A1 Myhrvold, Cameron
A1 Kemball, Molly E.
A1 Chaluvadi, Sushma
A1 Cusick, Caroline
A1 Flowers, Katelyn
A1 Neumann, Anna
A1 Cerrato, Felecia
A1 Farhat, Maha
A1 Slater, Damien
A1 Harris, Jason B.
A1 Branda, John
A1 Hooper, David
A1 Gaeta, Jessie M.
A1 Baggett, Travis P.
A1 O’Connell, James
A1 Gnirke, Andreas
A1 Lieberman, Tami D.
A1 Philippakis, Anthony
A1 Burns, Meagan
A1 Brown, Catherine M.
A1 Luban, Jeremy
A1 Ryan, Edward T.
A1 Turbett, Sarah E.
A1 LaRocque, Regina C.
A1 Hanage, William P.
A1 Gallagher, Glen R.
A1 Madoff, Lawrence C.
A1 Smole, Sandra
A1 Pierce, Virginia M.
A1 Rosenberg, Eric
A1 Sabeti, Pardis C.
A1 Park, Daniel J.
A1 Maclnnis, Bronwyn L.
YR 2020
UL http://medrxiv.org/content/early/2020/08/25/2020.08.23.20178236.abstract
AB SARS-CoV-2 has caused a severe, ongoing outbreak of COVID-19 in Massachusetts with 111,070 confirmed cases and 8,433 deaths as of August 1, 2020. To investigate the introduction, spread, and epidemiology of COVID-19 in the Boston area, we sequenced and analyzed 772 complete SARS-CoV-2 genomes from the region, including nearly all confirmed cases within the first week of the epidemic and hundreds of cases from major outbreaks at a conference, a nursing facility, and among homeless shelter guests and staff. The data reveal over 80 introductions into the Boston area, predominantly from elsewhere in the United States and Europe. We studied two superspreading events covered by the data, events that led to very different outcomes because of the timing and populations involved. One produced rapid spread in a vulnerable population but little onward transmission, while the other was a major contributor to sustained community transmission, including outbreaks in homeless populations, and was exported to several other domestic and international sites. The same two events differed significantly in the number of new mutations seen, raising the possibility that SARS-CoV-2 superspreading might encompass disparate transmission dynamics. Our results highlight the failure of measures to prevent importation into MA early in the outbreak, underscore the role of superspreading in amplifying an outbreak in a major urban area, and lay a foundation for contact tracing informed by genetic data.Competing Interest StatementJ.E.L. has received consulting fees from Sherlock Biosciences. J.B. has been a consultant for T2 Biosystems, DiaSorin, and Roche Diagnostics. A.P. is a Venture Partner at Google Ventures. P.C.S. is a co-founder and shareholder of Sherlock Biosciences, and a Board member and shareholder of Danaher Corporation.Funding StatementFunding: This work was sponsored by the National Institute of Allergy and Infectious Diseases (U19AI110818 to P.C.S; R37AI147868 to J.L.), the National Human Genome Research Institute (K99HG010669 to S.K.R.), the National Institute of General Medical Sciences of the National Institutes of Health (U54GM088558 W.P.H.), the Centers for Disease Control and Prevention (U01CK000490; MGH), the Bill and Melinda Gates Foundation (Broad Institute), and the US Food and Drug Administration (HHSF223201810172C), with in-kind support from Illumina, Inc., as well as support from the Doris Duke Charitable Foundation (J.E.L.), the Howard Hughes Medical Institute (P.C.S.), the Herchel Smith Fellowship (K.A.L.), and the Evergrande COVID-19 Response Fund Award from the Massachusetts Consortium on Pathogen Readiness (J.L). The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This study was approved by the Partners Institutional Review Board under protocol 2019P003305 and Massachusetts Department of Health under MDPH IRB 00000701.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesInteractive phylogenetic trees are available at auspice.broadinstitute.org. Assembled genomes and raw metagenomic reads from this dataset have been deposited at NCBI Genbank and SRA databases under BioProject PRJNA622837 with NIAID Data Sharing policy. Experimental protocols are publicly available on Benchling and can be accessed at the link below. https://benchling.com/sabetilab/f_/gaLGu5X9-sabeti_group_sars-cov-2_metagenomic_sequencing_protocols/ https://auspice.broadinstitute.org